Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
150 stopped studies mapped to Hodgkin Lymphoma and descendants · 86% state a reason
Over the 150 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01468311 | Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's… | Phase 1 / Phase 2 | terminated | Nov 9, 2011 | National Cancer Institute (NCI) | Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR)… | Enrollment / accrual |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | Phase 2 | terminated | Jan 11, 2010 | University of Liege | recruitment too slow | Enrollment / accrual |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT00992030 | R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma | Phase 3 | terminated | Oct 8, 2009 | Fondazione Michelangelo | Low recruitment and difficulty in having study data | Enrollment / accrual |
| NCT02867618 | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | Phase 1 / Phase 2 | terminated | Aug 16, 2016 | Columbia University | PI left institution | Investigator |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT03154710 | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of… | N/A | terminated | May 16, 2017 | Weprom | Negative interim analysis | Efficacy / futility |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT01652261 | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)(H11) | Phase 3 | withdrawn | Jul 30, 2012 | European Organisation for Research and Treatment of Cancer - EORTC | Study closed due to lack of recruitment | Enrollment / accrual |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT04373083 | Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical… | Phase 2 | withdrawn | May 4, 2020 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT01121120 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell…(TXA127-PBSC) | Phase 2 | terminated | May 12, 2010 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT02875067 | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients… | Phase 1 / Phase 2 | terminated | Aug 23, 2016 | NYU Langone Health | Merck's decision for early termination of the data | Other (stated, no rule matched) |
| NCT02624258 | Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory… | Early Phase 1 | terminated | Dec 8, 2015 | University of Pennsylvania | Principal Investigator decision to stop trial | Investigator |
| NCT02603419 | Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma… | Phase 1 | terminated | Nov 11, 2015 | Pfizer | The study was terminated due to lack of recruitment. | Enrollment / accrual |
| NCT00860171 | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating… | Phase 1 | terminated | Mar 12, 2009 | Fred Hutchinson Cancer Center | Terminated due to lack of funding | Funding |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for… | Phase 1 | terminated | Jun 1, 2012 | Barbara Ann Karmanos Cancer Institute | Low accrual. No Analyses were performed | Enrollment / accrual |
| NCT01742793 | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid)…(RID) | Phase 1 | terminated | Dec 5, 2012 | Yale University | The study was terminated due to withdrawal of institutional support, Phase II never began. | Other (stated, no rule matched) |
| NCT03471351 | Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in… | Phase 1 | terminated | Mar 20, 2018 | Rhizen Pharmaceuticals SA | At this point, the current study in HL does not fit into clinical development and regulatory… | Sponsor / business decision |
| NCT00973804 | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched… | Phase 1 | terminated | Sep 9, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02254239 | Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Oct 1, 2014 | Mayo Clinic | funding withdrawal | Funding |
| NCT03120676 | Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma | Phase 2 | terminated | Apr 19, 2017 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT00866333 | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or…(ENGAGE-501) | Phase 2 | terminated | Mar 20, 2009 | Syndax Pharmaceuticals | Terminated prior to completion of accrual per corporate decision. | Enrollment / accrual |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 | terminated | Jan 13, 2006 | Masonic Cancer Center, University of Minnesota | Drug was not available. | Other (stated, no rule matched) |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT02763254 | Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas(CIVIC) | Phase 2 | terminated | May 5, 2016 | Cell Medica Ltd | Insufficient recruitment rate | Enrollment / accrual |
| NCT02378922 | Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated… | Phase 1 | withdrawn | Mar 4, 2015 | Fred Hutchinson Cancer Center | Administratively closed prior to subject enrollment | Enrollment / accrual |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT02343666 | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With… | Phase 1 | withdrawn | Jan 22, 2015 | Fred Hutchinson Cancer Center | Administrative closure prior to any enrollments | Enrollment / accrual |
| NCT00129753 | Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant… | Phase 2 | withdrawn | Aug 12, 2005 | M.D. Anderson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00901303 | Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan… | N/A | terminated | May 13, 2009 | Weill Medical College of Cornell University | The study was terminated due to lack of accrual. | Enrollment / accrual |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood… | Phase 2 | terminated | Dec 10, 2012 | Weill Medical College of Cornell University | Slow accrual | Enrollment / accrual |
| NCT01326728 | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | — | terminated | Mar 31, 2011 | National Cancer Institute (NCI) | A replacement protocol was created to replace this current version of protocol. | Other (stated, no rule matched) |
| NCT00984165 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic… | Phase 2 | terminated | Sep 25, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual, PI left NIH and primary endpoint not met. | Investigator |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | Phase 1 / Phase 2 | terminated | Feb 29, 2008 | Milton S. Hershey Medical Center | Investigator decision | Investigator |
| NCT00909948 | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following…(RLI) | Phase 1 | terminated | May 29, 2009 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT01929941 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced… | Phase 1 | terminated | Aug 28, 2013 | Incyte Corporation | Business decision. | Sponsor / business decision |
| NCT03205891 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin… | Phase 1 | withdrawn | Jul 2, 2017 | M.D. Anderson Cancer Center | Change in treatment priorities for these disease types as well as staffing concerns. | Other (stated, no rule matched) |
| NCT02456675 | INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory… | Phase 2 | terminated | May 28, 2015 | Incyte Corporation | A decision was made to terminate the study due to the changing treatment landscape for the… | Other (stated, no rule matched) |
| NCT01636388 | Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus… | Phase 2 | terminated | Jul 10, 2012 | New York Medical College | funding ended | Funding |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | Phase 2 | terminated | Apr 28, 2011 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT00722865 | Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for… | Phase 2 | terminated | Jul 28, 2008 | Massachusetts General Hospital | slow enrollment | Enrollment / accrual |
| NCT00837200 | Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | Phase 2 | terminated | Feb 5, 2009 | Milton S. Hershey Medical Center | PI said to close accrual do to funding | Enrollment / accrual |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 6, 2021source: clinicaltrials